Goodwin Advises Repligen Corporation on $1 Billion Convertible Senior Notes Offering

The Life Sciences and Capital Markets teams advised Repligen Corporation (Nasdaq: RGEN) (Repligen) on its offering of $1 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 (the New Notes). Approximately $541.4 million principal amount of the New Notes were issued in exchange for approximately $456.8 million principal amount of Repligen’s existing 1% convertible senior notes due 2028, and approximately $458.6 million principal amount of the New Notes were issued for cash. Repligen used approximately $120.0 million of the net proceeds from the offering to repurchase shares of its common stock from certain purchasers of the New Notes and intends to use the remainder of the net proceeds for working capital and general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services, and technologies.

Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions that support critical steps in the manufacturing and delivery of biologic drugs that improve human health worldwide. As a trusted partner to biopharmaceutical developers and manufacturers and CDMOs worldwide, Repligen helps improve productivity, simplify complex workflows, and advance the next generation of biologic therapies. Repligen technologies support the production of a broad range of biologic modalities, helping customers navigate evolving manufacturing challenges from process development through commercial production.

The Goodwin team was led by Jim Barri, Jon Burr, and Rachel Staats, with invaluable assistance from Jacqueline Mercier, Dan Karelitz, and Garrett Gaughan.

For more information on the deal, please read the press release.